The global male contraceptives market is expected to rise from USD 16.5 billion in 2026 to reach USD 38.6 billion by 2040, growing at a CAGR of 6.3% over the forecast period 2026 to 2040, driven by reversible product innovation. Based on duration of action, single-use coital methods capture 72.0% market share in 2026, whereas on-demand pharmacological methods register a 38.3% CAGR through 2040, reducing adherence burdens. Based on distribution channel, drugstores and retail pharmacies capture 33...

The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035. Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. In...

The global T-Cell Engagers Market reached USD 8.6 billion in 2026 and is projected to reach USD 62.5 billion by 2040, growing at a CAGR of 15.2% over the forecast period 2026 to 2040, driven by expanding hematologic approvals and early solid-tumor validation. Hematology-led adoption has shifted the T-cell engagers market from niche leukemia use toward broader CD3-directed bispecific commercialization. CD20, BCMA, and GPRC5D products now anchor demand across lymphoma and myeloma. DLL3 validation...

The global AI in medical scribing market reached USD 1.82 billion in 2026 and is projected to reach USD 22.3 billion by 2040, growing at a CAGR of 19.6% over the forecast period 2026 to 2040, driven by clinician burnout reduction and EHR-native ambient documentation. Ambient clinical documentation is moving from transcription replacement to EHR-integrated clinical workflow automation. Hospitals first bought AI medical scribe software to reduce note burden and after-hours charting.

The global peptide synthesis market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 6.0 billion by 2035, at a CAGR of 4.1% during the forecast period 2026 to 2035. The generics segment secures 88% of the overall revenue share primarily due to the patent expirations of first-generation peptide drugs and high costs associated with branded therapies. In terms of type of peptide synthesis method, chemical synthesis method currently holds 85% of the overall m...

The back of the eye disorders market, valued at USD 17.06 billion in 2025, is projected to reach USD 18.28 billion in 2026 and USD 41.56 billion by 2035, representing a CAGR of 9.6% during the forecast period 2026 to 2035. Kindly note that implants and devices related to the back of the eye disorders market have been excluded from the scope of this report. In terms of geographical regions, North America captures around 60% of the market value in the year 2026, due to strong public and private i...

The global triage system market is estimated at USD 9.8 billion in 2026 and is projected to reach USD 42.2 billion by 2040, growing at a CAGR of 11.0% over the forecast period 2026 to 2040, driven by AI-enabled emergency department prioritization, virtual front-door triage, and EHR-integrated decision-support tools. Regulatory classification and workflow validation slow adoption because triage tools influence patient routing and clinical prioritization. Infermedica’s September 2025 MDR Class I...

The global biopharmaceutical excipients manufacturing market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 6.3 billion by 2035, representing a CAGR of 6.4% during the forecast period 2026 to 2035. Emerging innovations, particularly in lipid-based excipients for mRNA vaccines and therapeutics, are further expanding the excipient landscape. Coupled with the rising trend in outsourcing and growing regulatory support for novel excipients, the use of biopha...

The global AI in medical coding market is expected to rise from USD 3.4 billion in 2026 and reach USD 16.2 billion by 2040, growing at a CAGR of 11.8% over the forecast period 2026 to 2040, driven by revenue cycle automation and coder productivity pressure. Based on Component, Software platforms is both the dominant and fastest-growing category, holding 72.0% share in 2026 and expanding at 12.4% CAGR through 2040, driven by scalable autonomous coding engines. Compliance exposure restrains autono...

The global atrial fibrillation treatment devices market, valued at USD 7.9 billion in 2025, is projected to reach USD 9.6 billion in 2026 and USD 29.0 billion by 2035, representing a CAGR of 13.1% during the forecast period 2026 to 2035. Atrial fibrillation currently affects tens of millions of individuals worldwide, with global prevalence estimates exceeding 50 million cases. Driven by the aging populations and growing prevalence of hypertension, obesity, diabetes, and unhealthy lifestyles, the...

The global atrial fibrillation market, valued at USD 20.9 billion in 2025, is projected to reach USD 21.4 billion in 2026 and USD 38.7 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. The market includes both treatment drugs and devices for atrial fibrillation (AFib). In 2024, the CDC identified AFib as the most common heart arrhythmia treated in the US. The number of Americans affected is projected to reach 12.1 million by 2030, with AFib contributing to rou...

The global bioanalytical testing services market, valued at USD 4.94 billion in 2025, is projected to reach USD 5.38 billion in 2026 and USD 10.90 billion by 2035, representing a CAGR of 8.2% during the forecast period. Based on the type of molecule, the global market is segmented into small molecules, large molecules and others. According to our projections, small molecules segment currently holds 56% of the bioanalytical testing services market share. As per our global bioanalytical testing se...

The large molecule bioanalytical testing services market, valued at USD 2.89 billion in 2025, is projected to reach USD 3.11 billion in 2026 and USD 5.88 billion by 2035, representing a CAGR of 7.3% during the forecast period 2026 to 2035. In terms of end-user, the pharmaceutical and biotechnology companies account for around 50% of the overall revenue share. In terms of geographical regions, North America holds close to 50% of the market share due to its strong public and private investments, s...

The global microbial fermentation CMO market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.3 billion in 2026 and USD 9.6 billion by 2035, with a CAGR of 9.4% during the forecast period 2026 to 2035. Presently, there are a number of traditional and innovative microbial expression systems / platforms, based on bacteria, fungi and yeast, which are used for manufacturing a variety of conventional and complex biologics. Contract manufacturers engaged in this domain have forged sever...

The global clinical workflow solutions market is expected to rise from USD 14.8 billion in 2026 to reach USD 71.7 billion by 2040, growing at a CAGR of 11.9% over the forecast period 2026 to 2040, driven by EHR-integrated automation, cloud deployment, and AI-enabled documentation. The clinical workflow solutions market is shifting from fragmented messaging and data tools into AI-enabled operating layers. Hospitals now need platforms that connect EHR data, alerts, documentation, orders, analytics...

The global connected medical device cybersecurity market reached USD 9.7 billion in 2026 and is projected to reach USD 50.0 billion by 2040, growing at a CAGR of 12.43% over the forecast period 2026 to 2040, driven by rising IoMT exposure, FDA cybersecurity requirements, and hospital network risk. Based on geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 14.9% CAGR through 2040, driven by hospital digitization and regulatory catch-up. Based on applic...

The global cancer biomarkers market, valued at USD 24.5 billion in 2025, is projected to reach USD 25.9 billion in 2026 and USD 37.8 billion by 2035, representing a CAGR of 4.3% during the forecast period 2026 to 2035. In December 2025, Lunit partnered with Daiichi Sankyo to accelerate biomarker discovery and optimize translational research by integrating its multiple AI-powered Lunit SCOPE digital pathology products across its two oncology pipeline programs.  In July 2025, Tianfu Wu (an associ...

The quantum computing in drug discovery market, valued at USD 315 million in 2025, is projected to reach USD 361 million in 2026 and USD 1,692 million by 2035, representing a CAGR of 18.7% during the forecast period 2026 to 2035. In terms of geographical regions, North America captures more than 40% of the market value in the year 2026, due to its strong public and private investments, supportive regulations, and significant funding. In February 2026, XtalPi entered into a collaboration with VIS...

The global liquid biopsy market, valued at USD 8.20 billion in 2025, is projected to reach USD 9.49 billion in 2026 and USD 33.45 billion by 2035, representing a CAGR of 15.0% during the forecast period 2026 to 2035. Liquid biopsy solutions offer a minimally invasive and accessible method for early cancer detection and patient monitoring. This is primarily because of their superior ability to perform high-throughput multi-gene profiling, the ongoing reduction in sequencing costs, and its high se...

The global cancer metabolism based therapeutics market, valued at USD 2.7 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 26.3 billion by 2035, with a CAGR of 24.3% during the forecast period 2026 to 2035. With respect to route of administration, oral route (close to 85%) dominates the current market. Based on target disease indication, in 2026, breast cancer captures the largest cancer metabolism based therapeutics market value (over 45%). In terms of geographical regions...